Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-418-6 | CAS number: 55965-84-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1993-11-03 till 1994-01-07
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: .
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-3 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- One non-pregnant female inadvertently sacrified on day 17 p.c. On day 10 p.c. 2 animals incorrectly dosed (dosage appr. 4 % higher).One female rat of the control group, which littered, had a body weight of 262 g due to pregnancy.
- GLP compliance:
- yes
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
Sprague Dawley Crl: CD (SD)BR, from “specific pathogen free" colony
- Source: Charles River Wiga GmbH, 97633 Sulzfeld, Germany
following data only for females; males were not treated with the test article and were used for mating only
- Age at study initiation: : 8 to 12 weeks
- Weight at study initiation: 180 to 238 g
- Housing: individually in macrolon III-cages on autoclaved sawdust
- Diet (e.g. ad libitum): ad lib. Ssniff R10 standard diet
- Water (e.g. ad libitum): ad lib. tap water
- Acclimation period: 7 days prior to mating
ENVIRONMENTAL CONDITIONS
- Temperature (°C): (17) 19-25°C
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light):12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: daily
VEHICLE
aqua bidestillata - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- first and last week of treatment; analysed by HPLC-UV;
result: analytical conc. =92-98% of nominal dose - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:4
- Length of cohabitation: during the night
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of gestation - Duration of treatment / exposure:
- 10 days, from day 6 - 15 post-coitum; 5 days postexposure-period;
- Frequency of treatment:
- daily for 10 consecutive days
- Duration of test:
- (23 d in total)
- No. of animals per sex per dose:
- 25 inseminated females per group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- day 20 post-coitum: sacrificed
Examinations
- Maternal examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily
BODY WEIGHT: Yes
- Time schedule for examinations:Individually for days 0, 6, 9, 12, 16 and 20 post-coitum
FOOD CONSUMPTION: Yes Individually for the intervals from day 0-6, 6-9, 9-12, 12-16 and 16-20 post-coitum.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: only macroscopically for changes - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of life/dead fetuses: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Intra-uterine deaths were classified as follows:
Early resorptions showed decidual or placental tissues only.
Late resorptions showed embryonic or fetal tissue in addition to placental tissue but did not include fetuses dying in utero within approximately 2 days prior to the terminal kill.
Dead fetuses included only the fetuses dying in utero within approximately the last 2 days.
The uteri of apparently non-pregnant females were immersed in a 10 per cent solution of ammonium sulphide to reveal evidence of implantation (Salewski technique). - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: all per litter
- Head examinations: No data
- Sex
Approximately half of the fetuses from each litter were eviscerated and the carcasses processed for skeletal examination (Alizarin staining technique).
The remaining half was fixed in ethanol and examined for visceral abnormalities using a modified Wilson-Barrow technique.
Dead fetuses were evaluated separately, if applicable. Structural deviations were classified as follows:
Malformation: rare and/or probably lethal, e.g. hydrocephaly.
Variation: changes which regularly occur also in control groups and which are not of functional significance.
In one litter each from group 2 (animal 45) and 4 (animal 94) all fetusses were determined for visceral examination were inadvertently eviscerated. Therefore only visceral examination of the heads was possible. - Statistics:
- body weight, body weight change and food consumption: Levene's test for homogeneity of variances followed by rank transformation and the Levene's test in the case of heterogeneity only (p < 0.05, equivalent to 95 per cent confidence level) and ANOVA with Dunnett's two-tailed t-test to compare each treated group against the control group.
litter weight: the Bartlett's test for homogeneity of variance followed by rank transformation andBartlett's test in the case of heterogeneity only (p < 0.05, equivalent to 95 per cent confidence level) ;IF homogen: ANOVAwith Dunnett's two-tailed t-test was used to compare each treated group against the control group; IF heterogen Kruskal-Wallis test with Wilcoxon rank-sum test to compare each treated group against the control group.
number of corpora lutea, number of implantations, pre-implantation loss, total intra-uterine deaths, post-implantation loss, number of live fetuses and proportion of male fetuses: rank transformation followed by the Bartlett's test for homogeneity of variances. IF homogeneous: ANOVA, followed in the case of significant results (p < 0.05, equivalent to 95 per cent confidence level) by the Dunnett's two-tailed t-test to compare each treated group against the control group. IF heterogen: rank transformed data the Kruskal-Wallis test together with the Wilcoxon rank-sum test to compare each treated group against the control group.
mean fetal: rank transformation followed by the Bartlett's test for homogeneity of variances ANCOVA (covariate: number of fetuses). with Dunnett's two-tailed t-test was used to compare each treated group against the control group.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
No mortalities were observed in this study.
CLINICAL OBSERVATIONS
Treatment-related clinical signs were observed in groups 3 (70 mg/kg) and 4 (139 mg/kg).
In group 3 (70 mg/kg), two animals showed gasping and/or wheezing respiration shortly after dosing an 1 or 2 days at the beginning of the treatment period. During the further course of treatment no compound-related clinical signs were observed.
In group 4 (139 mg/kg), six animals showed gasping and/or wheezing respiration shortly after dosing for 1 to 5 days. Mostly these signs were observed at the beginning of treatment but two animals showed them also during the second half of the treatment period.
In group 2 (28 mg/kg), no treatment-related clinical signs were observed.
BODY WEIGHT
Group mean body weight gain was slightly affected by treatment with Acticide 14 in groups 2 (28 mg/kg) and 3 (70 mg/kg), and moderately affected in group 4 (139 mg/kg).
In groups 2 (28 mg/kg) and 3 (70 mg/kg), mean body weight gain was slightly reduced from day 6 to 9 post-coitum. During the further course of treatment it was comparable to that in the control group. Evaluation for the entire treatment-period as well as for the entire study revealed a slight reduction of mean body weight gain in these groups.
In group 4 (139 mg/kg), mean body weight gain was moderately and statistically significantly reduced from day 6 to 9 post-coitum and slightly reduced from day 12 to 16 post-coitum. In consequence, mean body weight gain was also reduced from day 6 to 16 post-coitum and from day 0 to 20 post-coitum.
FOOD CONSUMPTION
A minimal to slight effect of treatment with Acticide 14 an mean daily food consumption was observed in all dose groups.
In groups 2 (28 mg/kg) and 3 (70 mg/kg), mean daily food consumption was minimally lower than the control group from day 6 to 9 post-coitum, which is considered to be treatment related. During the further course of the study food consumption in these groups was comparable to that in the control group.
In group 4 (139 mg/kg), mean daily food consumption was slightly reduced from day 6 to 9 post-coitum and slightly and statistically significantly reduced from day 12 to 16 post-coitum. Consequently, evaluation for the entire treatment-period as well as the entire study revealed a slight reduction of food consumption in this group.
NECROPSY FINDINGS
Necropsy did not reveal any treatment-related findings. In one animal each from group 3 (70 mg/kg) and 4 (139 mg/kg) findings in the kidneys and/or liver were detected. These single observations are considered to be incidental and not attributable to treatment with Acticide 14.
Effect levels (maternal animals)
- Dose descriptor:
- LOAEL
- Effect level:
- 28 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
IMPLANTATION
No effect of treatment with Acticide 14 on implantation data was observed. The pre-implantation loss was comparable and within the normal range in all groups.
POST-IMPLANTATION LOSS
The post-implantation loss was not affected by treatment with Acticide 14. The observed inter-group differences are considered to be incidental.
NUMBER, SEX AND WEICHT OF THE FETUSES
No effect of treatment with Acticide 14 was observed on number, sex and weight of the fetuses.
The mean number of fetuses per litter was comparable in all groups.
The fetal sex distribution in the dose groups was comparable to that in the control group.
The mean fetal weight was similar in all groups.
FETAL DEFECTS
Fetal examination did not reveal any treatment-related malformations or variations. External, visceral and skeletal malformations were found in all groups including the control group.
In group 2 (28 mg/kg), two malformed fetuses were found in two different litters. In one fetus a single common ventricle of the heart was detected at visceral examination. The second fetus showed skeletally absent rib(s).
In group 3 (70 mg/kg), three fetuses with malformations were detected in three different litters. In two fetuses malformations such as asplenia or anorchism were detected at visceral examination. Externally, the third fetus showed microtia and anasarca. Visceral examination of this fetus did not reveal any further findings.
In group 4 (139 mg/kg), two malformed fetuses were found in two different litters. One fetus showed microsplenia at visceral examination. Externally, the second fetus showed agnathia. Visceral examination of this fetus revealed malformations such as anophthtalmia, aglossia and nares non-patent.
One control fetus showed anal atresia as an external malformation.
Visceral or skeletal variations were detected in fetuses of all study groups.
The type and the incidence of the observed malformations and variations did not show a dose-relationship and did not indicate any effect of treatment with Acticide 14.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 19.6 mg/kg bw/day
- Basis for effect level:
- other: embryotoxicity
- Dose descriptor:
- NOAEL
- Effect level:
- >= 19.6 mg/kg bw/day
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Administration of Acticide 14 to pregnant rats during the phase of organogenesis did not result to observation of any signs of teratogenicity or embryotoxicity.
- Executive summary:
The potential of a 14% aqueous solution of 3 parts 5 -chloro- 2 -methyl-2H-isothiazol-3 -one and 1 part 2 -methyl-2H-isothiazol-3 -one (cited as Acticide 14 in the report) to induce teratogenic effects in rats was evaluated in a study according to guideline EPA OPP 83 -3. Pregnant female Sprague-Dawley rats were treated with the test substance by oral gavage during the period of organogenesis (days 6 -15 post coitum). Animals were observed for mortality, signs of toxicity, food consumption and body weight gain during the treatment and a post-exposure period of 5 days. At day 20 of gestation, animals were sacrificed and examined for macroscopic pathological abnormalities. Uterine contents were examined for signs abnormal pregnancy courses, and fetuses were examined for external, visceral and skelettal abnormalities.
Treatment with the test article resulted in maternal toxicity with clearly distingished dose-dependent grades of severity (clinical signs, moderately reduced body weight gain, slightly reduced food consumption). In spite of the observed adverse maternal effects, treatment with the test article did not have any influence on the embryonic and fetal development, as there was no embryotoxicity and no teratogenicity detected in any of the dose groups.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies